Michael DeLong is an Assistant Professor-in-Residence in the Division of Plastic Surgery at UCLA David Geffen School of medicine. He completed medical school at Duke University, followed by a competitive six-year integrated residency in plastic and reconstructive surgery at the prestigious University of California Los Angeles. He was selected to continue at UCLA for an additional year of microsurgery fellowship to develop expertise in complex reconstruction. During residency, Dr. DeLong achieved the award for the highest in-service exam score every year taken.
Dr. DeLong has broad clinical interests and expertise including breast reconstruction, head and neck reconstruction, orthopedic reconstruction, gender affirmation, and face, breast, and body cosmetics. He is dedicated to bringing his patients the best clinical care, informed by the latest research and the most up-to-date clinical practices.
Dr. DeLong is an active NIH-funded researcher advancing the field of plastic surgery. He has been the principal investigator on seven separate grants and has several publications in top plastic surgery journals. He has already won numerous awards and recognition for his scientific contributions including Best Breast Paper in Plastic and Reconstructive Surgery Journal 2020, the Bernard Sarnat Award for Grant Writing Excellence in 2019, and a feature in the nationally distributed Plastic Surgery News. Dr. DeLong has been invited to serve on several professional society committees, is a reviewer for multiple scientific journals, and is on the editorial board for research of the Annals of Plastic Surgery.
Dr. DeLong has become a recognized expert in plastic surgery medical devices and regulatory science. During his residency, he took a one-year hiatus to complete a fellowship at the Food and Drug Administration in the Center for Devices and Radiological Health. After completion of this fellowship, his expertise was further requested and he has been appointed as one of seven voting members of the FDA General and Plastic Surgery Devices Panel, which provides recommendations to FDA for complex devices issues.